Neuralink’s most recent primary funding round closed in mid-2025 at a $9 billion valuation following a $650 million Series E, more than doubling the prior $3.5–5 billion marks from 2023. Trader sentiment centers on continued clinical momentum, with 21 participants enrolled across trials in multiple countries and two FDA Breakthrough Device Designations for speech and vision restoration applications. Plans for high-volume automated production in 2026 and expanding international sites signal a shift toward commercialization that could support further valuation growth. Secondary-market indications have hovered near $10 billion with occasional unconfirmed reports of higher levels, while total funding now exceeds $1.3 billion. Key upcoming catalysts include additional regulatory clearances, patient outcome data, and any potential follow-on capital raise ahead of year-end resolution.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado↑$100B
10%
↑$75B
29%
↑$60B
39%
↑$50B
58%
↓$35B
54%
↓$32.5B
99%
↓$25B
12%
NPM Prices are published for trading days only and are updated once daily at 1:00 PM ET on the following calendar day.
If NPM has not published relevant data for all business dates in the specified period by 1:00 PM ET on January 1, 2027, this market may remain open until 11:59 PM ET on January 4, 2027. If no further data is released by that time, the market will resolve according to the data available.
If NPM ceases publishing relevant data prior to the end of the specified period, this market will resolve based on the NPM data published for the period prior to the cessation of coverage, as well as any applicable public market capitalization data following an IPO or direct listing.
If the company completes an IPO or direct listing before the end of the specified period, this market will consider, in addition to the relevant NPM valuations published between market creation and the IPO or direct listing date, the valuation implied by the official IPO or direct listing price, and the company's public market capitalization between the IPO or direct listing date and the end of the specified period.
Public market capitalization will be determined using the highest/lowest official regular-hours trading price published for the company's primary listed common equity on its primary exchange for any trading day during the specified period, multiplied by the company's total outstanding common shares at the relevant time.
If the listed company merges with or acquires another entity and remains the parent company, no change to resolution methodology applies.
If the listed company is acquired, merges into another entity and is no longer the surviving parent company, or otherwise ceases to exist as an independent entity prior to the end of the period, only NPM valuations and applicable public market capitalizations achieved prior to completion of the transaction will be considered for resolution. No transaction, acquisition, or merger consideration will be considered for resolution.
The resolution source for this market is NPM data published here (https://fe.secondmarket.com/companies/company-782c0a32-4727-4097-a40b-9a2602f243e7/data). The resolution source for any period following an IPO, direct listing, or relevant corporate action, will be official exchange trading data and publicly reported share counts.
Revisions to previously published NPM data made after their initial release will not be considered, unless made to correct clearly erroneous data.
Mercado abierto: May 19, 2026, 1:02 AM ET
Resolver
0x65070BE91...NPM Prices are published for trading days only and are updated once daily at 1:00 PM ET on the following calendar day.
If NPM has not published relevant data for all business dates in the specified period by 1:00 PM ET on January 1, 2027, this market may remain open until 11:59 PM ET on January 4, 2027. If no further data is released by that time, the market will resolve according to the data available.
If NPM ceases publishing relevant data prior to the end of the specified period, this market will resolve based on the NPM data published for the period prior to the cessation of coverage, as well as any applicable public market capitalization data following an IPO or direct listing.
If the company completes an IPO or direct listing before the end of the specified period, this market will consider, in addition to the relevant NPM valuations published between market creation and the IPO or direct listing date, the valuation implied by the official IPO or direct listing price, and the company's public market capitalization between the IPO or direct listing date and the end of the specified period.
Public market capitalization will be determined using the highest/lowest official regular-hours trading price published for the company's primary listed common equity on its primary exchange for any trading day during the specified period, multiplied by the company's total outstanding common shares at the relevant time.
If the listed company merges with or acquires another entity and remains the parent company, no change to resolution methodology applies.
If the listed company is acquired, merges into another entity and is no longer the surviving parent company, or otherwise ceases to exist as an independent entity prior to the end of the period, only NPM valuations and applicable public market capitalizations achieved prior to completion of the transaction will be considered for resolution. No transaction, acquisition, or merger consideration will be considered for resolution.
The resolution source for this market is NPM data published here (https://fe.secondmarket.com/companies/company-782c0a32-4727-4097-a40b-9a2602f243e7/data). The resolution source for any period following an IPO, direct listing, or relevant corporate action, will be official exchange trading data and publicly reported share counts.
Revisions to previously published NPM data made after their initial release will not be considered, unless made to correct clearly erroneous data.
Resolver
0x65070BE91...Neuralink’s most recent primary funding round closed in mid-2025 at a $9 billion valuation following a $650 million Series E, more than doubling the prior $3.5–5 billion marks from 2023. Trader sentiment centers on continued clinical momentum, with 21 participants enrolled across trials in multiple countries and two FDA Breakthrough Device Designations for speech and vision restoration applications. Plans for high-volume automated production in 2026 and expanding international sites signal a shift toward commercialization that could support further valuation growth. Secondary-market indications have hovered near $10 billion with occasional unconfirmed reports of higher levels, while total funding now exceeds $1.3 billion. Key upcoming catalysts include additional regulatory clearances, patient outcome data, and any potential follow-on capital raise ahead of year-end resolution.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado

Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes